Novo Nordisk (NVO) slashed the price of its weight-loss blockbuster, Wegovy, by more than half on Wednesday amid a bitter rivalry with pharmaceutical compounder Hims & Hers Health (HIMS).
Novo Nordisk launched an online pharmacy called NovoCare Pharmacy. Cash-paying patients can order all doses of the weight-loss drug for $499 per month. That's at a steep discount to the list price, which doesn't take into account insurance or discounts, of $1,349 for a 28-day supply.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?The news was a blow to Hims stock, which tumbled 5.7% to 38.19. The Food and Drug Administration recently determined the active ingredient behind Wegovy, semaglutide, is no longer in shortage. This means Hims & Hers will soon have to stop selling lower-cost versions of the same dosages Novo sells.
Hims has said it plans to focus on personalized semaglutide doses. But the price-cut Wegovy could sway some patients to buy from the original manufacturer. Novo reiterated safety concerns with "fake or illegitimate" compounded semaglutide in its news release.
"NovoCare Pharmacy offers reliable access to authentic, FDA-approved Wegovy in our once-weekly, single-dose pen," the company said.
In early trades, Novo Nordisk stock popped 3.9% to 90.93.
More to follow.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Illumina Recoups Losses After China Retaliates Against Trump's Tariffs
Looking For The Next Big Stock Market Winners? Start With These 3 Steps
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Follow Premarket And After-The-Open Action With IBD Experts
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。